No intervention, observation only.
OtherObservation only
NCT Number: NCT04681690
The G-NeSS Registry prospectively collects data on clinical and outcome variables from patients undergoing partial nephrectomy for renal masses. Analyses of data aims at identifying key factors determining the quality of surgical care in this patient population.
Interested in participating?
Request Info18 year–100 year
All sexes
Observational
Sana Klinikum Hof, Hof, Bavaria, Germany
Today the majority of patients with renal tumors is diagnosed with localized disease amenable to nephron-sparing surgery (NSS). Partial nephrectomy (PN) constitutes the reference standard treatment for small renal masses according to international guidelines. Open PN ist still the predominant apporach in Germany, but the use of minimally-invasive surgery has continously increased over the last decades. Specifically, robotic surgery is on the rise and may facilitate the adoption of a minimally-invasive PN approach even in more complex renal tumours. Real world data on the outcomes of PN according to the surgical approach are limited. Data from cancer registries and health insurance databases usually lack important information an key patient und tumour characteristics, such as tumour complexity.
The G-NESS registry database aims at prospectively collecting such clinical and outcome data from patients undergoing PN. Data collection includes perioperative variables on patient characteristics, tumour location and complexity, surgical approach, intra-/postoperative complications, and kidney function. Follow-up based on questionnaires is conducted after predefined intervals (i.e. 30 days, 12 months, 24 months, and 60 months) in order to receive information on long-term kidney function, comorbidities, and survival. The information received from the database can help to better define the optimal surgical care for patients with renal masses.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Observation only
Time frame: 60 months
Complication rate according to Clavien-Dindo in %
Time frame: 60 months
Rate in ml/min.
Time frame: 60 months
Overall Survival
Contact information is provided by the study sponsor or research team.
Heidrun Rexer
CONTACT
039827/79 677
Nina Harke, Dr.
CONTACT
0511/532 ext. 36 47
Association of Urologic Oncology (AUO)
Other
German National Registry for Nephron-Sparing Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07397611
Adenocarcinoma, Carcinoma
Boston, Massachusetts, United States
View Trial DetailsNCT02346435
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Baltimore, Maryland, United States
View Trial DetailsNCT07234409
Behavior, Deception
Milan, Italy
View Trial DetailsNCT06903312
Adenocarcinoma, Carcinoma
Roma, Italy
View Trial Details